Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326728 · ClinicalTrials.gov registry record
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
A clinical trial, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- 56
- Enrollment target
NCT01326728: Clinical Trial study, sponsored by National Cancer Institute (NCI).
NCT01326728 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01326728 was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- 56 participants
- Enrollment target
Study Summary
Background: Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells) have been used with varying degrees of success as an immune therapy for blood-system cancers (leukemias, myelodysplastic syndrome, lymphomas, multiple myeloma, etc.). Some people s cancer remains active (comes back or continues to spread) after an allotransplant, while other peoples cancer disappears and they are hopefully cured. National Institutes of Health (NIH) researchers are studying the reasons for these different treatment outcomes, and trying to develop better cancer treatments for people with active cancer after allotransplant. Researchers are collecting data from people who have had allotransplants for a cancer of the blood, whether or not the cancer is in remission, and from their donors. Those with active cancers may be eligible to participate in one of several NIH studies testing treatments for active cancer after allotransplant. Objectives: * To develop a systematic, comprehensive evaluation of individuals with relapsed malignant blood cancers after allotransplant (and, if available, their donors) to identify potential treatment study options * To compare the immune system after allotransplant between people whose cancers are growing with people whose cancers remain in remission. * To compare the immune system after cancer relapse/progression treatment between people whose cancer responds to treatment with those whose cancers continue to grow. Eligibility: * Individuals whose blood system cancer grows or comes back after receiving allotransplant treatment. * Individuals whose blood system cancer is responding or in remission 100 days or more after receiving allotransplant treatment. * Related stem-cell donors of eligible allotransplant recipients. Design: * Participants will be evaluated with a full physical examination, detailed medical history (for recipients, including a history of allotransplant treatment process, side-effects, etc.),
Primary Outcome
Biological response to agents and or treatments that can lead to bone marrow suppression/ cytopenias and sometimes death.
Interventions
- BIOLOGICAL Allogeneic stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2011-03-30 |
| Est. Completion | 2017-07-14 |
Why NCT01326728 stopped before completion
NCT01326728 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic stem cell transplant is the first listed.
NCT01326728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01326728 about?
NCT01326728 is a clinical study titled "Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation". Background: Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells) have been used with varying degrees of success as an immune therapy for blood-system cancers (leukemias, myelodysplastic syndrome, lymphomas, multiple myeloma, etc.). Some people s cancer rema...
What is the current status of trial NCT01326728?
This trial is currently terminated. The enrollment target is 56 participants. The study started on 2011-03-30. Estimated completion is 2017-07-14.
What interventions are being tested in trial NCT01326728?
The interventions under investigation include: Allogeneic stem cell transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01326728?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI